CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

The majority of non–small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. Unfortunately, a subset of patients with EGFR mutations are refractory to EGFR-TKIs. Resis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Park, Kang-Seo, Raffeld, Mark, Moon, Yong Wha, Xi, Liqiang, Bianco, Caterina, Pham, Trung, Lee, Liam C., Mitsudomi, Tetsuya, Yatabe, Yasushi, Okamoto, Isamu, Subramaniam, Deepa, Mok, Tony, Rosell, Rafael, Luo, Ji, Salomon, David S., Wang, Yisong, Giaccone, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4071378/
https://ncbi.nlm.nih.gov/pubmed/24911146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI73048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados